Skip to main content
AskVantage

Virtual worlds

Virtual reality is helping scientists discover new drugs faster

Discovering new drugs is a laborious and expensive process, but VR is helping make it significantly faster and cheaper.

Key takeaways

  • Biochemists are also using the technology to develop drugs to tackle other diseases, such as cancer and Parkinson's.
  • A brief example of how it works The key to drug design is finding the right shape for the molecule to fit inside the targeted protein pocket.
  • The company claims that the technology could help to reduce the margin of error during the drug discovery process and enable scientists in different locations to work on drug models in the same virtual room.
Cite or link to this article

Griffin, M. (2019) 'Virtual reality is helping scientists discover new drugs faster', 311 Institute, 17 July. Available at: https://www.311institute.com/virtual-reality-is-helping-scientists-discover-new-drugs/ (Accessed: 1 October 2026).

Virtual Reality (VR), the same technology that's revolutionising video games and cancer treatments by letting doctors literally "fly through cancers," is being used to develop new drugs and fight some of the world's deadliest diseases. And in time, as Artificial Intelligence (AI) augments and takes over from human scientists, from predicting the outcomes of organic reactions to creating complex molecules, this same technology could one day help AI's discover drugs millions of times faster than we do today by using it to run billions of drug simulations an hour.

Chemists at C4X Discovery have announced that they are using the VR technology behind popular game Fortnite to visualize the structure of complex molecules, and that the tool, called 4Sight, has already been used to create a drug that is now in development to treat addiction. Biochemists are also using the technology to develop drugs to tackle other diseases, such as cancer and Parkinson's.

Scientists traditionally used physical models to visualize drugs. But 4Sight allows drug developers to grab hold of virtual molecules and see how they move and respond to stimuli.

A brief example of how it works
 

The key to drug design is finding the right shape for the molecule to fit inside the targeted protein pocket. If you get the wrong shape, the molecule could fail to attach or even lodge in a different pocket, causing side effects.

"Moving molecules around that are very complicated is so much easier by grabbing them than by trying to use a mouse on a keyboard," says Craig Fox, chief scientific officer at C4X Discovery.

The company claims that the technology could help to reduce the margin of error during the drug discovery process and enable scientists in different locations to work on drug models in the same virtual room.

"It takes about 10 to 12 years to take a drug from the concept to the market," says Fox. "It's often described as trying to find a needle in a haystack."

It's also exceedingly expensive. It costs $2.6 billion on average to develop a new prescription medicine that gains market approval, according to the Tufts Center for Study of Drug Development, so anything that helps speed up the development process and make it less laborious for scientists is welcome. That's why C4X Discovery hired former video game developer Phil Muwanga for the job of lead coder.

"The software is the same as a game," says Muwanga, "we have a user base, we're trying to get them to do tasks over and over again. And we're trying to do it in a fun and intuitive fashion."

4Sight enables scientists to visualize the unique 4D data, that measures space and time as well as length, width and depth, that C4X Discovery has accumulated on small drug molecules.

"We are making a scientific tool that scientists will use to improve their daily lives," says Muwanga. "That being said I am from the games industry and I do treat this as a game, people interact with it in the same way."

VR has shown its potential in other areas of health care. It's been used as a tool for medical training, with students learning about the human anatomy through simulation. Surgeons can use it to prepare for complicated surgeries, and it's even been used as a tool for pain relief.

The global market for artificial and virtual reality in health care is projected to reach $5.1 billion by 2025, according to a 2017 report by Grand View Research, and even the biggest pharma companies recognize potential of virtual reality tools. Novartis, for example, is also using tit in the drug design process, and Pfizer has experimented with applications from clinical trial design to manufacturing.

"We believe immersive technologies can in the future provide cognitive behavioral assistance and even telehealth," says Jim Mangione, Pfizer's director of emerging technologies.

311 Intelligence

What this means for your organisation

Seeing molecules in 3D speeds design.

Handling a molecule in virtual space shows its shape and movement better than screens or models. Finding the right fit for a target gets faster. Research leaders should test immersive tools in early discovery.

Games technology crosses into science.

The same engines that power games now help design medicines. Tools built for entertainment can transform industry. Leaders should scan consumer technology for professional uses.

AI will build on immersive tools.

Combining immersive tools with AI could let machines run vast numbers of drug simulations. Human insight and machine scale can work together. Plan workflows where scientists and AI share the work.

Three questions for your next leadership meeting

  1. Could immersive tools speed up our early drug discovery?
  2. Which consumer technologies could serve our professional needs?
  3. How should our scientists and AI share research work?

The trends and technologies behind this story

From the 311 Starburst, the 311 Strategic Intelligence Unit’s map of the technologies and trends shaping the next 50 years.

Brief your leadership team on the future of workA private briefing on how AI and automation will change your workforce, and what to do now. In person first.
Book a Briefing

Analysis by the 311 Strategic Intelligence Unit, from Matthew Griffin’s article and 311 data. First published on Fanatical Futurist.

FAQ

Why does this matter?

Discovering new drugs is a laborious and expensive process, but VR is helping make it significantly faster and cheaper.

Matthew Griffin

About the author

Matthew Griffin Founder, President and Futurist, 311 Institute

Matthew Griffin is a multi-award winning Futurist and expert in Disruption and Innovation, Geopolitics, Leadership, and Technology, who NASA have described as a "walking encyclopaedia of the future" and a "futurist Polymath."

Read full bio

Matthew Griffin is a multi-award winning Futurist and expert in Disruption and Innovation, Geopolitics, Leadership, and Technology, who NASA have described as a "walking encyclopaedia of the future" and a "futurist Polymath." 17-time best selling author of the "Codex of the Future" series, Matthew is the Founder, President and Futurist of the 311 Institute, a global Futures and Deep Futures advisory firm working with royal households, world leaders, G7, G20, and G77 governments, NGOs, and multi-national mid and mega cap firms to help them explore, shape, and lead the next 50 years of business and society.

An award-winning YouTube creator with over a million followers, with an unrivalled global reach and impact, Matthew is a highly sought-after international keynote speaker, lecturer, and mentor who collaborates with global leaders through the United Nations Alliance of Civilizations (UNAOC) and United Nations General Assembly (UNGA) to shape pivotal initiatives such as the UN’s AI for Humanity program, the United Nations Conference of the Parties (UN COP), and the World Economic Forum in Davos.

As the former Global Head of Cloud, National Security, and Enterprise Sales for companies including Atos, Dell-EMC, and IBM, Matthew has a proven track record of building multi-billion dollar business units and turning failing divisions into market leaders. His ability to identify, analyse, and communicate the implications of hundreds of emerging technologies and trends is unparalleled, and his insights are trusted by many of the world’s most respected organisations, including ABB, Accenture, Adidas, AON, ARM, BCG, Centrica, Citi, Coca-Cola, Dentons, Deloitte, Dow Jones, EY, Google, KPMG, Lego, Legal & General, LinkedIn, Microsoft, PepsiCo, Qualcomm, RWE, Samsung, Siemens AG and Siemens Energy, T-Mobile, UBS, VISA, Walmart, Workday, Worldpay and many others.

Regularly featured in the global media including the AP, BBC, Bloomberg, CNBC, Discovery, Forbes, Khaleej Times, Telegraph, TIME, ViacomCBS, WIRED, and the WSJ, Matthews mission is to help organisations create a fair and sustainable future whose benefits are shared by everyone irrespective of their ability, background, or circumstances.

What future do you need to see?

Choose one to get started on virtual worlds and the future of your organisation.

Where should Matthew reply?

Takes 30 seconds. No obligation. Matthew replies quickly. Privacy

Tag Cloud

Dossier opens the 311 Starburst dossier for that technology or trend.

Sources and further reading

  1. C4X Discovery c4xdiscovery.com
  2. Tufts Center for Study of Drug Development static1.squarespace.com
  3. medical training medicalrealities.com
  4. Cedars sinai study finds virtual reality therapy helps decrease pain in hospitalized patients cedars-sinai.org
  5. Virtual reality vr in healthcare market grandviewresearch.com
  6. Bringing virtual reality lab novartis.com
  7. How virtual reality takes scientists inside new molecules pfizer.com

Source: first published by the 311 Institute on 17 July 2019. Cite as: Griffin, M. (2019). Virtual reality is helping scientists discover new drugs faster. 311 Institute. https://www.311institute.com/virtual-reality-is-helping-scientists-discover-new-drugs/

You are welcome to quote this article with credit and a link to the original.

Book a Keynote